|
February 10, 2012
|
| 11:58 EDT |  | PFE |
|
| 07:10 EDT |  | PFE |
|
|
February 9, 2012
|
| 16:27 EDT | | PFE |
| theflyonthewall.com: | Leerink's biotech and pharmaceuticals analysts hold a conference call | | Biotech Analysts Schimmer and Liang, along with Pharmaceuticals Analyst Fernandez, review the reimbursement process for drugs in France on an Analyst/Industry conference call. Relevant covered companies ACOR, AMGN, AMLN, AUXL, BIIB, BMY, GILD, HGSI, ITMN, JNJ, NVS, PFE and VRTX may be included on the Analyst/Industry conference call to be held on February 10 at 11 am. :theflyonthewall.com |
|
|
February 8, 2012
|
| 23:32 EDT |  | PFE |
|
| 07:29 EDT | | PFE |
| theflyonthewall.com: | Nestle battles Danone for Pfizer's infant nutrition business, Reuters reports |
 Subscribe for More Information :theflyonthewall.com |
|
|
February 2, 2012
|
| 10:14 EDT | | PFE |
|
| 07:36 EDT | | PFE |
| theflyonthewall.com: | Mylan receives tentative FDA approval for generic version of Pfizer's Lipitor |
Subscribe for More Information :theflyonthewall.com |
|
|
February 1, 2012
|
| 16:32 EDT | | PFE |
|
| 09:41 EDT |  | PFE |
| theflyonthewall.com: | Auxilium recieves cautious assessment for Xiaflex, says Leerink | | Leerink said the IQWiG released its assessment for Auxilium's/Pfizer's (PFE) Xiaflex for Dupuytren's contracture and Esai's Halavan for breast cancer. The firm said both received a "no proven added benefit" assessment and views the decision as concerning for the drugs and believes it reduces visibility into German reimbursement. :theflyonthewall.com |
|
| 08:00 EDT | | PFE |
|
| 05:28 EDT | | PFE |
| theflyonthewall.com: | Pfizer announces voluntary recall of Lo/Ovral-28, Norgestrel/Ethinyl Estradiol | | Pfizer has voluntarily recalled 14 lots of Lo/Ovral-28 Tablets and 14 lots of Norgestrel and Ethinyl Estradiol Tablets for customers in the U.S. market. An investigation by Pfizer found that some blister packs may contain an inexact count of inert or active ingredient tablets and that the tablets may be out of sequence. The cause was identified and corrected immediately. These packaging defects do not pose any immediate health risks. This recall is being conducted with the knowledge of the U.S. Food and Drug Administration. :theflyonthewall.com |
|
|
January 31, 2012
|
| 23:22 EDT | | PFE |
|
| 18:41 EDT | | PFE |
| theflyonthewall.com: | Pfizer announces birth control recall, Bloomberg reports | | Company recalls one million packages of birth control, saying they may have the wrong dose of medicine, according to Bloomberg. :theflyonthewall.com |
|
| 16:25 EDT |  | PFE |
| theflyonthewall.com: | On The Fly: Closing Wrap | | Stocks on Wall Street were mixed, as the Dow was weighed on by Exxon Mobil (XOM) and Pfizer (PFE), which both sold off following their quarterly reports. Stock futures were higher during the pre-market trading session but weakened slightly following the lower than expected results from the Case/Shiller Home Price survey. The market opened higher but never really gained any upside momentum. Shortly after the open, investors saw the release of the Chicago Purchasing Managers report, which came out well below expectations, followed by a lower than expected consumer confidence reading. The market lost all of its momentum and soon moved into negative territory. The averages drifted higher in the second half of the day, eventually turning mixed, though the Dow was unable to join the Nasdaq in the green... ECONOMIC EVENTS: In the U.S., home prices fell again in November according to the S&P/Case-Shiller index, which showed they declined 1.3% from the previous month. The Chicago Purchasing Managers report reading of 60.2 was below the expected reading of 63.0. The Conference Board's consumer confidence reading of 61.1 also disappointed, as analysts expected a reading of 68.0. In Europe, 25 of 27 EU members, excluding the U.K. and the Czech Republic, agreed in principle on elements of their eventual fiscal union... MARKET NEWS: The slide in shares of Exxon Mobil following its earnings report weighed on the Energy sector and on the Dow. The company's overall earnings and revenue beat estimates but its "downstream" profits plummeted from the same quarter last year... Fellow Dow component Pfizer reported earnings and sales that beat Street expectations but it cut its FY12 view, sending its stock lower... MAJOR MOVERS: Among the notable gainers were PAREXEL (PRXL), up $3.64, or 17.79%, to $24.10, after its Q2 revenues were significantly higher than forecast, and magicJack VocalTec (CALL), up $2.09, or 12.14%, to $19.30, after being initiated with an Outperform rating and $24 price target at Oppenheimer. Noteworthy losers included Polypore (PPO), down $16.26, or 29.92%, to $38.08, after one its customers, Korea's LG Chem, said it plans to enter the battery separator business, and RadioShack (RSH), down $3.05, or 29.81%, to $7.18, following its pre-announcement of Q4 results that fell well below expectations... INDICES: The Dow fell 20.81, or 0.16%, to 12,632.91; the Nasdaq rose 1.90, or 0.07%, to 2,813.84; and the S&P 500 lost 0.61, or 0.05%, to 1,312.40. :theflyonthewall.com |
|
| 15:56 EDT |  | PFE |
| theflyonthewall.com: | Options Update; January 31, 2012 | | CBOE Volatility Index-VIX up 2c to 19.42. Option volume leaders today: AMZN LVS PFE AAPL according to Track Data. :theflyonthewall.com |
|
| 12:16 EDT | | PFE |
|
| 10:56 EDT | | PFE |
| theflyonthewall.com: | Pfizer says hasn't decided on potential method of monetization for Animal Health |
Subscribe for More Information :theflyonthewall.com |
|
| 10:49 EDT | | PFE |
| theflyonthewall.com: | Pfizer says sees downward pressure on gross margin | | Sees ability to get operating margins in high 30s to low 40s. :theflyonthewall.com |
|
| 10:27 EDT | | PFE |
|
| 10:23 EDT | | PFE |
| theflyonthewall.com: | Pfizer sees consistent EPS growth "over time" | | :theflyonthewall.com |
|
| 10:20 EDT | | PFE |
|
| 10:17 EDT | | PFE |
|
| 10:10 EDT | | PFE |
|
| 10:09 EDT | | PFE |
| theflyonthewall.com: | Pfizer says will continue to return cash to shareholders via dividends, buybacks | | :theflyonthewall.com |
|
| 10:09 EDT | | PFE |
|
| 10:04 EDT | | PFE |
|
| 08:16 EDT | | PFE |
| theflyonthewall.com: | Glaxo, Lilly, Pfizer, others interested in MN Pharms stake, Businessweek says |
Subscribe for More Information :theflyonthewall.com |
|
| 07:15 EDT | | PFE |
| theflyonthewall.com: | Pfizer reports Q4 Primary Care revenue $5.41B, down 8% | | Specialty Care revenue fell 5% to $3.82B; Emerging Markets revenue down 4% to $2.26B; Established Products revenue $2.3B, down 5%. :theflyonthewall.com |
|
| 07:13 EDT | | PFE |
| theflyonthewall.com: | Pfizer reports Q4 Lipitor revenue $2B, Lyrica revenue $998M | | Reports Q4 Prevnar / Prevenar 13 revenue $834M; Enbrel sales outside U.S. and Canada $925M; Viagra revenue $523M; Celebrex revenue $667M. :theflyonthewall.com |
|
| 07:09 EDT |  | PFE |
| theflyonthewall.com: | Pfizer sees FY12 operating cash flow at least $19B | | :theflyonthewall.com |
|
| 07:09 EDT | | PFE |
|
| 07:08 EDT | | PFE |
|
| 07:07 EDT | | PFE |
| theflyonthewall.com: | Pfizer says on track with timeline for decisions on Animal Health, Nutrition | | The company says "We remain on-track with our timeline of finalizing strategic decisions for the Animal Health and Nutrition businesses this year and continue to expect that any separation of these businesses from Pfizer will occur between July 2012 and July 2013." :theflyonthewall.com |
|
| 07:06 EDT | | PFE |
|
| 07:06 EDT | | PFE |
|
| 07:06 EDT | | PFE |
|
|
January 30, 2012
|
| 13:20 EDT | | PFE |
|
| 12:40 EDT | | PFE |
| theflyonthewall.com: | Earnings Preview: Pfizer trading slightly lower ahead of Q4 earnings | | Pfizer (PFE) is expected to report Q4 earnings before the market open on Tuesday, January 31 with a conference call scheduled for 10:00 am ET. Analysts are looking for EPS of 47c on revenue of $16.61B. The consensus range is 43c-50c for EPS, and $15.9B-$17.18B for revenue, according to First Call. After reporting better-than-expected EPS and revenue in Q3, the company issued guidance for FY11 EPS of $2.24-$2.29 vs. consensus $2.28 and FY11 revenue $66.2B-$67.2B vs. consensus $67.24B. Looking forward, the company said there exists uncertainty around macroeconomic issues, including pricing pressures in Europe and volatility in emerging markets. At the JP Morgan Global Healthcare Conference, Pfizer said it's on track to announce a decision for its Animal Health unit. It will also make dividends, share repuchases and "bolt-on" acquisitions its priorities in FY12. In fact, it already raised the quarterly dividend to 22c per share, and targets a dividend buyout ratio of approximately 40% by the end of 2013. In the upcoming conference call, the company is expected to provide details on Lipitor sales numbers after losing exclusivity in late November. The company had said it still plans to market Lipitor, but will focus on remaking itself into a developer of biologic drugs and specialty medicines. Barron's said this transition into a leaner company is a great buying opportunity as Pfizer expands its sales into emerging markets. In the past quarter, the company announced positive results for Toviaz, Lyrica and Embeda, but disappointing results for its Apixaban trial. In recommendations, Pfizer was downgraded to Hold at Standpoint Research and Market Perform at Leerink, citing valuation and limited pipeline catalysts. Nonetheless, Credit Suisse said the company still has a strong profile particular with the commercial prospects for its Tofacitnib drug. :theflyonthewall.com |
|
| 08:15 EDT | | PFE |
|
| 05:57 EDT | | PFE |
|
